Clofenoxyde is antifungal and antibacterial agent developed in the 1960s. It is claimed to have activity against gram-positive and gram-negative bacteria.

Carmegliptin is a potent, long-acting, selective, orally bioavailable, pyrrolidinone-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. ). DPP-IV is a proline-specific serine protease enzyme that is known to rapidly inactivate two incretin hormones released during food ingestion, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Incretins are essential for regulating both fasting and postprandial plasma glucose by stimulating insulin secretion, supporting β-cell mass, and inhibiting glucagon production by the α-cells to reduce glucose production by the liver. By selectively inhibiting DPP-IV, carmegliptin prolongs the activity of circulating GLP-1 and GIP and improves their potential to prolong the antidiabetic actions. Carmegliptin is indicated for use as monotherapy or in combination with other oral antihyperglycemic agents for the treatment of Type 2 diabetes.

LEMIDOSUL is a loop diuretic, antihypertensive agent.

LAUROGUADINE is a bactericide, topical antiseptic.

LAFLUNIMUS is an immunomodulator with anti-inflammatory activities. It inhibits prostaglandin endoperoxide H synthases 1 and 2 in vitro and in vivo. It also acts as an immunosuppressive agent being an inhibitor of mitochondrial dihydroorotate dehydrogenase and concomitant reducing agent of pyrimidine nucleotide pools.

Motexafin is texaphyrin patented by pharmaceutical company Pharmacyclics, Inc. as chelating agents useful for the treatment of neoplastic and cardiovascular disease. The MRI-detectable gadolinium complex of motexafin was studied as a redox modulator that selectively targets tumor cells.

Nortopixantrone (BBR-3438), a member of the 9-aza-anthrapyrazole family, is a DNA topoisomerase inhibitor potentially designed for the treatment of gastric cancer, ovarian cancer. BR 3438 exhibited a unique profile of preclinical activity with a superior efficacy against prostatic carcinoma models compared to reference compounds (doxorubicin and losoxantrone). Nortopixantrone had been in phase II clinical trials with Novuspharma for the treatment of gastric cancer, ovarian cancer and prostate cancer. But this research was discontinued in 2002.

Metrenperone, a 5-hydroxytryptamine blocker, is used in veterinary as an antimyopathic agent. Experiments on rabbits have shown that the drug had positive effects on collagen turnover, remodeling, and organization during acute inflammation and fibroplasia.

Iodecimol is nonionic-dimeric contrast medium patented by Schering A.-G. for myocardial imaging

Leurubicin was developed as a prodrug of doxorubicin (Dox) with the aim of lowering the cardiotoxicity and improving the therapeutic index produced by Dox. Antineoplastic agent Dox was rapidly formed from leurubicin, reaching peak levels in plasma within 5 min and in tissues within 1 h after i.v. administration of leurubicin. The incorporation of leurubicin into the MES-SA human uterine sarcoma cell line and its Dox resistant counterpart, MES-SA/Dx5 cell line and the subsequent transformation of leurubicin into Dox and its subcellular distribution, were investigated. In both cell lines the cellular uptakes of Dox and leurubicin were similar at equimolar doses, while the percent transformation of leurubicin into Dox in MES-SA/Dx5 cells was about twice as great as its transformation in MES-SA cells, which is beneficial for reaching Dox cytotoxic levels in this resistant cell line. The highest Dox/ leurubicin ratio was found in the nuclear fraction, followed by the ratio in the low density organelle fraction that contains lysosomes, organelles in which lysosomal hydrolytic enzymes, capthesins, transform leurubicin into Dox.